Journal article
Disease-Modifying Therapeutic Concepts for HIV in the Era of Highly Active Antiretroviral Therapy
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, v 58(3)
01 Nov 2011
PMID: 21792065
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Chronic HIV infection is associated with persistent immune activation and inflammation even among patients virologically suppressed on antiretroviral therapy for years. Chronic immune activation has been associated with poor outcomes-both AIDS-defining and non-AIDS-defining clinical events-and persistent CD4 T-cell depletion. The cause of chronic immune activation in well-controlled HIV infection is unknown. Proposed drivers include residual viral replication, microbial translocation, and coinfecting pathogens. Therapeutic interventions targeting immune activation are emerging, from approaches that interfere directly with activation and inflammatory pathways to those that prevent microbial translocation or decrease the availability of host target cells for the virus. In the context of the disappointing results of the interleukin-2 trials, the main challenges to developing these disease-modifying therapies include identifying an adequate target population and choosing surrogate endpoints that will provide positive proof-of-concept that the interventions will translate into long-term clinical benefit before embarking on large clinical endpoint trials.
Metrics
Details
- Title
- Disease-Modifying Therapeutic Concepts for HIV in the Era of Highly Active Antiretroviral Therapy
- Creators
- Scott L. Butler - Pfizer (United Kingdom)Hernan Valdez - Pfizer,Michael Westby - Pfizer,Manos Perros - AstraZenecaCarl H. June - University of PennsylvaniaJeffrey M. Jacobson - Drexel UniversityYves Levy - Paris-Est SupDavid A. Cooper - UNSW SydneyDaniel Douek - National Institutes of HealthMichael M. Lederman - Case Western Reserve UniversityPablo Tebas - University of Pennsylvania
- Publication Details
- JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, v 58(3)
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 7
- Grant note
- Pfizer, Inc.; Pfizer Pfizer Global Research and Development; Pfizer
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:000296383900021
- Scopus ID
- 2-s2.0-80054962584
- Other Identifier
- 991019335242304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Immunology
- Infectious Diseases